Over € 4 million for cancer research in Utrecht
Over € 4 million for cancer research in Utrecht
The Dutch Cancer Society (DCS) is investing 4.4 million in 8 studies at Utrecht Science Park. It concerns 5 studies at UMC Utrecht, 2 at the Hubrecht Institute and 1 at the Helen Dowling Institute.
UMC Utrecht is very grateful for all the generous donations to the Dutch Cancer Society. The funding of these studies enables us to realize our goal to continuously improve the outcome of patients with cancer.
The approved applications for UMC Utrecht are:
EUS-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction.
Prof. Frank Vleggaar and Dr. Hjalmar van Santvoort.
How do hereditary LKB1 mutations lead to an increased risk of colon cancer?
Prof. dr. Madelon Maurice and prof. dr. ir. Edwin Cuppen.
Reinforcing the toxicity of T or NK cells to eradicate cancer cells and prevent outgrowth
Dr. Victor Peperzak and Dr. Zsolt Sebestyen.
NEN-ID: Identifying the origin, prognosis and treatment opportunities of metastatic neuroendocrine tumors with DNA methylation profiles
Dr. Lodewijk Brosens.
Optimizing a new form of immunotherapy for patients with colon cancer: TEGs
Prof. Dr. Jürgen Kuball together with Prof. Dr. Hans Clevers, Dr. Florijn Dekkers, Dr. Anne Rios, Dr. Jarno Drost, Dr. Karijn Suijkerbuijk and Dr. Zsolt Sebestyen.